A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations

Medicare's process for determining the prices for the first set of medicines subject to negotiation under the Inflation Reduction Act will be just as important to many in industry as the actual price.

Thus, how much Medicare and the drug companies involved can and are willing to reveal is likely to be a debate target as the US Centers for Medicare and Medicaid implements its new authorities for the first time